New company in type 2 diabetes development

One of the world’s top twenty leading pharmaceutical groups, Boehringer Ingelheim, is entering the type 2 diabetes drug market. The company plans to develop diabetes drugs, revealing plans for a novel type of oral antidiabetic compound which have already reached phase 2/3 of clinical testing.
The firm has been on a period of expansion into new treatment areas, unveiling a cancer drug development programme just two years ago. The move into diabetes drug development will be conducted with ‘great pleasure’ according to the vice-chariman of the board responsible for running the company.
Dr. Andreas Barner reportedly commented: “Boehringer Ingelheim is scientifically, economically and intellectually well-prepared to successfully [broaden] its diabetes pipeline to meet the needs of physicians and their patients.”